Skip to main content
SpringerLink
Log in

Bevacizumab + capecitabine not cost effective in mCRC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The MAX trial was supported by an unrestricted educational grant from Roche Products Pty Limited Australia and an additional untied educational grant from Roche Products Ltd UK.

Reference

  • Carter HE, et al. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer : 8 Nov 2013. Available from: URL: http://dx.doi.org/10.1016/j.ejca.2013.09.028

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bevacizumab + capecitabine not cost effective in mCRC. PharmacoEcon Outcomes News 692, 12 (2013). https://doi.org/10.1007/s40274-013-0906-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0906-4

Search

Navigation